Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. The focus is on setting realistic expectations for these treatments.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

Concerns about the legitimacy of pyrilutamide solutions from Farmacia Tristaina due to low prices and lack of testing. Users suggest using Jano testing for product verification.

Hair loss is linked to DHT, with treatments like finasteride and minoxidil being common but not definitive. Economic interests influence research, and there is potential for new treatments like PP405 and RU58841.

User tried various hair loss treatments with limited success. RU58841 was effective but caused side effects, now trying Eucapil and continuing Finasteride.

The user shares their experience with hair loss treatments, including oral finasteride, oral minoxidil, and a topical lotion for dandruff, expressing dissatisfaction with past treatments like PRP and hair transplants. They seek advice on a DNA test to determine suitable medications and express frustration with dermatologists' advice.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

The user is considering liposomal minoxidil due to non-response and side effects from other treatments. They are exploring tretinoin with topical minoxidil as an alternative.

A 16-year-old is experiencing hair loss and is using minoxidil, finasteride, and plans to add RU58841, while considering other treatments like MK-677 and microneedling. Concerns are raised about the potential impact of these treatments on puberty and development.

The conversation is about the progress of clinical trials for SCUBE3, a potential hair loss treatment. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation is about exploring alternatives for hair loss treatment, specifically ds laboratory revita shampoo and nanoxidil, with the user currently using microneedling. The user is considering these options due to fewer side effects compared to other treatments.

The conversation discusses the safety and trustworthiness of ordering RU58841 from Lyphar Biotech in China, with a focus on pricing and reliability. The user is seeking advice on whether to proceed with the purchase or consider alternative sources.

User wants to add RCP to regimen and asks if it can be applied with topical minoxidil and/or finasteride at night.

A human trial of verteporfin, a drug that can inhibit wound healing by scarring and promote regeneration of original tissue and hair follicles to provide an unlimited source for hair transplants; people discussed the potential of this drug and how it could be rolled out in mainstream with more doctors getting on board.

The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.

RU58841 from Amazon is unreliable, with users reporting no benefits and side effects like eye swelling and chest pain. Rudirect is recommended for purchasing in Europe.

The user received a Fagron TrichoTest indicating that Finasteride, Dutasteride, and Minoxidil are not effective for them, recommending Latanoprost, Spironolactone, IGrantine-F1 TM, and Trichoxidil instead. Other users expressed skepticism about the test's validity and suggested sticking with proven treatments like Finasteride and Dutasteride.

The results of using Pyrilutamide, a hair loss treatment available on the gray market, and other treatments such as Minoxidil, Finasteride and RU58841.

Treatments for hair loss, with the user considering Pyrilutamide and RU58841 as options. It is noted that although Pyrilutamide has been studied more and is allegedly more effective, there are doubts about its authenticity in the market. KX-826 is suggested as an alternative as it has a stronger effect than RU58841 and there is scientific research on it.

Using Pyrilutamide or RU as monotherapy for hair loss? Share experiences.

Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.

The conversation is about when the phase 3 results for pyrilutamide, a potential hair loss treatment, will be released. There was a letter about the study a month ago, but the actual results were not included.

Some people don't see results with FDA-approved hair loss treatments like finasteride or minoxidil due to underlying issues. The video suggests addressing these issues, especially if there are atypical symptoms or other health conditions.

Low doses of dutasteride are as effective as higher doses for hair regrowth, with fewer side effects. Users find success taking it 2-3 times a week instead of daily.

Hair loss discussion involved Finasteride, Minoxidil, and RU58841. User experienced sudden shedding after 1.5 years of Finasteride and Minoxidil use, seeking advice.

The conversation discusses using USB microscopes for scalp photos and provides a link to an overview of trichoscopy. Treatments mentioned include Minoxidil, finasteride, and RU58841.

Caffeine is not a proven DHT blocker and does not effectively treat hair loss. Minoxidil, finasteride, and RU58841 are more reliable treatments.

PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.

The conversation discusses the effectiveness of adding RCP (redensyl, capixyl, procapil) to a hair loss treatment regimen that includes minoxidil and finasteride. Users share experiences, suggesting RCP may not be as effective as minoxidil, but could be useful for creating topical solutions.